TrialsgrambetaRCTs are beautiful

SOUL

2025

A Heart Disease Study of Semaglutide in Patients with Type 2 Diabetes (Semaglutide cardiOvascular oUtcomes triaL)

In 9,650 patients with type 2 diabetes and ASCVD, CKD, or both, oral semaglutide reduced major adverse cardiovascular events compared with placebo (HR 0.86, 95% CI 0.77-0.96).

Result

Efficacy: Composite of CV death, nonfatal MI, or nonfatal stroke (3-point MACE)HR 0.86 (95% CI 0.77-0.96) · P = 0.006

Below 1 favours oral semaglutide, above 1 favours placebo.

Event rates
Absolute difference
1.8 points
NNT
56

Absolute difference and NNT are derived from the event rates.

Also reported: Over mean 47.5 months, a 14% relative risk reduction driven largely by fewer MIs.

Original publication
Subtopic
oral GLP-1 RA
Design
Double-blind placebo-controlled RCT, event-driven superiority
Relevance
Important: one of several pillars.
Source
McGuire DK, Marx N, Mulvagh SL, et al. N Engl J Med. 2025;392(20):2001-2012.doi 10.1056/NEJMoa2501006

Discussion & critique

MACE benefit modest and driven mainly by the MI component with no reduction in CV or all-cause death, and most patients were not on SGLT2 inhibitors at baseline. First CVOT to show an oral GLP-1 agonist lowers cardiovascular events.

Discussed in podcasts